{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:31:33Z","timestamp":1776843093615,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1007\/s40265-019-01080-6","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T09:02:17Z","timestamp":1551690137000},"page":"447-454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma"],"prefix":"10.1007","volume":"79","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"key":"1080_CR1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): multiple myeloma (version 2.2019). 2018. \nhttp:\/\/www.nccn.org\n\n. Accessed 7 Feb 2019."},{"issue":"9","key":"1080_CR2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia. 2017;31(9):1915\u201321.","journal-title":"Leukemia."},{"issue":"Suppl 6","key":"1080_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 6):52\u201361.","journal-title":"Ann Oncol."},{"issue":"1","key":"1080_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12254-018-0383-3","volume":"11","author":"E Willenbacher","year":"2018","unstructured":"Willenbacher E, Balog A, Willenbacher W. Short overview on the current standard of treatment in newly diagnosed multiple myeloma. Memo. 2018;11(1):59\u201364.","journal-title":"Memo."},{"key":"1080_CR5","doi-asserted-by":"crossref","unstructured":"Chari A, Mehra M, Slavcev M, et al. Evaluation and comparison of characteristics and outcomes among frontline multiple myeloma (FLMM) patients with and without stem cell transplant treatment [abstract no. 4738]. In: 60th American Society of Hematology Annual Meeting and Exposition. 2018.","DOI":"10.1182\/blood-2018-99-113176"},{"issue":"5","key":"1080_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/2040620718761776","volume":"9","author":"S Mahajan","year":"2018","unstructured":"Mahajan S, Tandon N, Kumar S. The evolution of stem-cell transplantation in multiple myeloma. Ther Adv Hematol. 2018;9(5):123\u201333.","journal-title":"Ther Adv Hematol."},{"key":"1080_CR7","unstructured":"American Cancer Society. Multiple myeloma. 2018. \nhttps:\/\/www.cancer.org\n\n. Accessed 7 Feb 2019."},{"key":"1080_CR8","doi-asserted-by":"crossref","unstructured":"Fonseca R, Usmani SZ, Mehra M, et al. Characterization of frontline treatment patterns and attrition rates by lines of therapy in non-transplant patients with newly diagnosed multiple myeloma [abstract no. 3291]. In: 60th American Society of Hematology Annual Meeting and Exposition. 2018.","DOI":"10.1182\/blood-2018-99-113125"},{"issue":"4","key":"1080_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","volume":"121","author":"P Lin","year":"2004","unstructured":"Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121(4):482\u20138.","journal-title":"Am J Clin Pathol."},{"key":"1080_CR10","unstructured":"Janssen Pharmaceutical. Darzalex (daratumumab): US prescribing information. 2015. \nhttps:\/\/www.janssenmd.com\n\n. Accessed 18 Feb 2019."},{"issue":"1","key":"1080_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13\u201329.","journal-title":"Blood."},{"issue":"18","key":"1080_CR12","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s40265-017-0837-7","volume":"77","author":"HA Blair","year":"2017","unstructured":"Blair HA. Daratumumab: a review in relapsed and\/or refractory multiple myeloma. Drugs. 2017;77(18):2013\u201324.","journal-title":"Drugs."},{"key":"1080_CR13","unstructured":"European Medicines Agency. Darzalex: summary of product characteristics. 2018. \nhttp:\/\/www.ema.europa.eu\n\n. Accessed 18 Feb 2019."},{"key":"1080_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01228","author":"T Plesner","year":"2018","unstructured":"Plesner T, Krejcik J. Daratumumab for the treatment of multiple myeloma. Front Immunol. 2018. \nhttps:\/\/doi.org\/10.3389\/fimmu.2018.01228\n\n.","journal-title":"Front Immunol."},{"key":"1080_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40267-016-0346-x","volume":"32","author":"K McKeage","year":"2016","unstructured":"McKeage K, Lyseng-Williamson KA. Daratumumab in multiple myeloma: a guide to its use as monotherapy in the EU. Drugs Ther Perspect. 2016;32:463\u20139.","journal-title":"Drugs Ther Perspect."},{"issue":"3","key":"1080_CR16","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840\u20138.","journal-title":"J Immunol."},{"issue":"2","key":"1080_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs. 2015;7(2):311\u201321.","journal-title":"mAbs."},{"issue":"3","key":"1080_CR18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38\u2009+\u2009immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384\u201394.","journal-title":"Blood."},{"issue":"3","key":"1080_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","volume":"197","author":"MB Overdijk","year":"2016","unstructured":"Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor-mediated cross-linking. J Immunol. 2016;197(3):807\u201313.","journal-title":"J Immunol."},{"issue":"8","key":"1080_CR20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754\u201366.","journal-title":"N Engl J Med."},{"issue":"10","key":"1080_CR21","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/leu.2015.123","volume":"29","author":"IS Nijhof","year":"2015","unstructured":"Nijhof IS, Groen RW, Lokhorst HM, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29(10):2039\u201349.","journal-title":"Leukemia."},{"issue":"7","key":"1080_CR22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof IS, Casneuf T, van Velzen J, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959\u201370.","journal-title":"Blood."},{"issue":"23","key":"1080_CR23","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","volume":"1","author":"T Casneuf","year":"2017","unstructured":"Casneuf T, Xu XS, Adams HC 3rd, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017;1(23):2105\u201314.","journal-title":"Blood Adv."},{"issue":"6 Pt 2","key":"1080_CR24","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/trf.13069","volume":"55","author":"CI Chapuy","year":"2015","unstructured":"Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55(6 Pt 2):1545\u201354.","journal-title":"Transfusion."},{"key":"1080_CR25","unstructured":"Janssen Pharmaceutical. Darzalex\u00ae (daratumumab): product information. 2017. \nhttps:\/\/www.janssen.com\n\n. Accessed 7 Feb 2019."},{"issue":"6","key":"1080_CR26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","volume":"54","author":"C McCudden","year":"2016","unstructured":"McCudden C, Axel AE, Slaets D, et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med. 2016;54(6):1095\u2013104.","journal-title":"Clin Chem Lab Med."},{"issue":"8","key":"1080_CR27","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","volume":"56","author":"PL Clemens","year":"2016","unstructured":"Clemens PL, Yan X, Lokhorst HM, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment. Clin Pharmacokinet. 2016;56(8):915\u201324.","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"1080_CR28","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/cpt.577","volume":"101","author":"XS Xu","year":"2017","unstructured":"Xu XS, Yan X, Puchalski T, et al. Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed\/refractory multiple myeloma. Clin Pharmacol Ther. 2017;101(6):721\u20134.","journal-title":"Clin Pharmacol Ther."},{"issue":"4","key":"1080_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40262-017-0598-1","volume":"57","author":"X Yan","year":"2018","unstructured":"Yan X, Clemens PL, Puchalski T, et al. Influence of disease and patient characteristics on daratumumab exposure and clinical outcomes in relapsed or refractory multiple myeloma. Clin Pharmacokinet. 2018;57(4):529\u201338.","journal-title":"Clin Pharmacokinet."},{"issue":"11","key":"1080_CR30","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s12325-018-0815-9","volume":"35","author":"XS Xu","year":"2018","unstructured":"Xu XS, Dimopoulos MA, Sonneveld P, et al. Pharmacokinetics and exposure-response analyses of daratumumab in combination therapy regimens for patients with multiple myeloma. Adv Ther. 2018;35(11):1859\u201372.","journal-title":"Adv Ther."},{"issue":"6","key":"1080_CR31","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518\u201328.","journal-title":"N Engl J Med."},{"issue":"9","key":"1080_CR32","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906\u201317.","journal-title":"N Engl J Med."},{"key":"1080_CR33","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Mateos MV, Cavo M, et al. One-year update of a phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): ALCYONE [abstract no. 156]. In: 60th American Society of Hematology Annual Meeting and Exposition. 2018.","DOI":"10.1182\/blood-2018-156"},{"key":"1080_CR34","doi-asserted-by":"crossref","unstructured":"Gries K, Fastenau J, Chen Y, et al. Health-related quality of life in patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation: results from the ALCYONE trial [abstract no. 8042]. J Clin Oncol. 2018;36(15 Suppl).","DOI":"10.1200\/JCO.2018.36.15_suppl.8042"},{"issue":"8","key":"1080_CR35","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol."},{"key":"1080_CR36","doi-asserted-by":"crossref","unstructured":"San-Miguel JF, Facon T, Dimopoulos MA, et al. Treatment regimens for patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation: a systematic literature review and network meta-analysis [abstract no. 4741]. In: 60th American Society of Hematology Annual Meeting and Exposition. 2018.","DOI":"10.1182\/blood-2018-99-113668"},{"key":"1080_CR37","unstructured":"Kumar SK, Plesner T, Orlowski RZ, et al. Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA) [abstract no. LBA-2]. In: 60th Annual Meeting & Exposition Of The American Society Of Hematology. 2018."},{"issue":"24","key":"1080_CR38","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1182\/blood-2016-09-692947","volume":"128","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Harousseau JL. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood. 2016;128(24):2757\u201364.","journal-title":"Blood."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01080-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01080-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01080-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T11:24:54Z","timestamp":1598268294000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01080-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,3,1]]}},"alternative-id":["1080"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01080-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]},"assertion":[{"value":"4 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yahiya Y Syed is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}